search
Back to results

Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer

Primary Purpose

Prostate Cancer

Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
bicalutamide
enzastaurin hydrochloride
Sponsored by
Eastern Cooperative Oncology Group
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Prostate Cancer focused on measuring stage I prostate cancer, stage II prostate cancer, stage III prostate cancer, recurrent prostate cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

DISEASE CHARACTERISTICS:

  • Histologically confirmed prostate cancer

    • Hormone-sensitive disease, as evidenced by a serum total testosterone level > 150 ng/dL
    • No evidence of metastatic disease on physical exam, CT abdomen/pelvis (or MRI), chest x-ray or CT scan and bone scan within 6 weeks prior to randomization
  • Underwent prior definitive surgery or radiotherapy

  • Must have evidence of biochemical failure after primary therapy and subsequent progression as determined by 1 of the following:

    • Prostate-specific antigen (PSA) ≥ 0.4 ng/mL (in case of radical prostatectomy)
    • PSA rise ≥ 2 ng/mL above the nadir PSA (in case of radiotherapy)
  • Baseline PSA must be at least 2 ng/mL and no greater than 50 ng/mL
  • PSA doubling time (PSADT) < 12 months

PATIENT CHARACTERISTICS:

  • ECOG performance status 0 - 1
  • Granulocytes ≥ 1,500/mm^3
  • Platelet count ≥ 75,000/mm^3
  • Serum creatinine normal or creatinine clearance ≥ 60 mL/min
  • Serum total bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • Alkaline phosphatase ≤ 2.5 times ULN
  • SGOT and SGPT < 2.5 times ULN
  • PT/INR normal
  • Fertile patients must use effective barrier contraception during and for at least 3 months after completion of study treatment
  • No gastrointestinal (GI) tract disease resulting in: inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, or uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis)
  • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to enzastaurin hydrochloride or bicalutamide

  • No uncontrolled intercurrent illness including, but not limited to, any of the following:

    • Ongoing or active infection
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia
    • Psychiatric illness/social situations that would limit compliance with study requirements
  • A history of other malignancy is permitted if the patient is predicted to be disease-free for 2 years

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • More than 4 weeks since prior salvage therapy with intent to cure (i.e., surgery, radiotherapy, or other local ablative procedures)
  • More than 4 weeks since prior prophylactic radiotherapy to prevent gynecomastia
  • More than 1 year since prior therapy modulating testosterone levels (such as luteinizing-hormone releasing-hormone agonists/antagonists and antiandrogens) unless in the neoadjuvant or adjuvant setting
  • No 5 alpha reductase inhibitors, ketoconazole, megestrol acetate, systemic steroids, or herbal supplements during PSA value collection

  • At least 14 days since prior enzyme-inducing anti-epileptic drugs (EIAEDs)

    • Patients who must begin EIAED therapy while on study are allowed to remain
  • No concurrent combination antiretroviral therapy for HIV-positive patients

  • No concurrent anticoagulant therapy

    • Low dosage acetyl salicylic acid ≤ 325 mg/day allowed
  • No other concurrent investigational agents or anticancer therapy (i.e., chemotherapy, immunotherapy, radiotherapy, surgery for cancer, or experimental medications)
  • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to enzastaurin or bicalutamide
  • Prior neoadjuvant and/or adjuvant therapy ≤ 4 weeks prior to randomization (i.e., hormones, chemotherapy, vaccines, or experimental agents) allowed if PSA rise and PSADT were documented after testosterone level was > 150 ng/dL

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    Arm A

    Arm B

    Arm Description

    Patients are observed without treatment in weeks 1-12. Patients with a prostate-specific antigen (PSA) rise of > 50% above baseline or nadir (whichever is lowest) and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, may be started on bicalutamide before the end of week 12 at the discretion of the treating physician. In weeks 13-44, patients with a rise PSA ≥ 50% above baseline or nadir, and a PSA rise of at least 5 ng/mL confirmed by a repeat PSA at least 2 weeks later, are removed from study. Patients receive oral bicalutamide once daily. Patients achieving a PSA decline ≥ 50% in the absence of toxicity may continue to receive bicalutamide up to 72 weeks.

    In weeks 1-12, patients receive oral enzastaurin hydrochloride twice daily. Patients with a PSA rise of > 50% above baseline or nadir, and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, may be started on bicalutamide before the end of week 12 at the discretion of the treating physician. In weeks 13-44, patients with a PSA rise of ≥ 50% above baseline or nadir, and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, are removed from study. Patients receive oral enzastaurin twice daily and oral bicalutamide once daily. Patients achieving a PSA decline ≥ 50% in the absence of toxicity may continue on this combination therapy up to 72 weeks.

    Outcomes

    Primary Outcome Measures

    Comparison of proportion of patients with undetectable prostate-specific antigen PSA level (< 0.2 ng/mL) at 44 weeks

    Secondary Outcome Measures

    Comparison of proportion of patients achieving ≥ 85% PSA decline at 44 weeks
    PSA response
    Time to PSA progression
    Time to PSA nadir
    Duration of PSA response
    PSA slope at baseline, during, and after treatment
    Effect of Gleason score and prior hormonal therapy on PSA response to treatment

    Full Information

    First Posted
    May 24, 2008
    Last Updated
    August 16, 2013
    Sponsor
    Eastern Cooperative Oncology Group
    Collaborators
    National Cancer Institute (NCI)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00685633
    Brief Title
    Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer
    Official Title
    Phase II, Randomized Study of Patients With Rising PSA at High-Risk of Progression After Primary Therapy to Assess the Clinical and Molecular Efficacy of the Enzastaurin - Bicalutamide Combination to Suppress the Androgen Receptor Without Testosterone Ablation
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2008
    Overall Recruitment Status
    Withdrawn
    Study Start Date
    December 2008 (undefined)
    Primary Completion Date
    June 2010 (Anticipated)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Eastern Cooperative Oncology Group
    Collaborators
    National Cancer Institute (NCI)

    4. Oversight

    5. Study Description

    Brief Summary
    RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving bicalutamide together with enzastaurin is more effective than bicalutamide alone in treating prostate cancer. PURPOSE: This randomized phase II trial is studying bicalutamide to see how well it works compared with giving bicalutamide together with enzastaurin in treating patients with prostate cancer.
    Detailed Description
    OBJECTIVES: Primary To compare the two regimens on the proportion of patients with undetectable prostate-specific antigen (PSA) level (< 0.2 ng/mL) at 44 weeks. Secondary To assess the proportion of patients with PSA decline > 85% at 44 weeks on the combination therapy arm compared to that of bicalutamide monotherapy arm. To assess the distribution of best PSA response in each study arm. To assess the time to PSA progression and the time to PSA nadir in each arm of the study. To assess the duration of PSA response in each arm of the study. To characterize the PSA slope before, during, and after treatment. To evaluate the safety and tolerability of enzastaurin hydrochloride in this patient population. To determine whether Gleason score or prior hormonal therapy has any effect on PSA response to treatment. OUTLINE: This is a multicenter study. Patients are stratified according to Gleason score (≤ 6 vs 7 vs 8-10) and prior hormonal therapy (yes vs no). Patients are randomized to 1 of 2 treatment arms. Arm A: Weeks 1-12: Patients are observed without treatment. Patients with a prostate-specific antigen (PSA) rise of > 50% above baseline or nadir (whichever is lowest) and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, may be started on bicalutamide before the end of week 12 at the discretion of the treating physician. Weeks 13-44: Patients with a rise PSA ≥ 50% above baseline or nadir, and a PSA rise of at least 5 ng/mL confirmed by a repeat PSA at least 2 weeks later, are removed from study. Patients receive oral bicalutamide once daily. Patients achieving a PSA decline ≥ 50% in the absence of toxicity may continue to receive bicalutamide up to 72 weeks. Arm B: Weeks 1-12: Patients receive oral enzastaurin hydrochloride twice daily. Patients with a PSA rise of > 50% above baseline or nadir, and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, may be started on bicalutamide before the end of week 12 at the discretion of the treating physician. Weeks 13-44: Patients with a PSA rise of ≥ 50% above baseline or nadir, and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, are removed from study. Patients receive oral enzastaurin twice daily and oral bicalutamide once daily. Patients achieving a PSA decline ≥ 50% in the absence of toxicity may continue on this combination therapy up to 72 weeks. After completion of study treatment, patients are followed every 3 months for 5 years, and then every 6 months for up to 10 years.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Prostate Cancer
    Keywords
    stage I prostate cancer, stage II prostate cancer, stage III prostate cancer, recurrent prostate cancer

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Arm A
    Arm Type
    Active Comparator
    Arm Description
    Patients are observed without treatment in weeks 1-12. Patients with a prostate-specific antigen (PSA) rise of > 50% above baseline or nadir (whichever is lowest) and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, may be started on bicalutamide before the end of week 12 at the discretion of the treating physician. In weeks 13-44, patients with a rise PSA ≥ 50% above baseline or nadir, and a PSA rise of at least 5 ng/mL confirmed by a repeat PSA at least 2 weeks later, are removed from study. Patients receive oral bicalutamide once daily. Patients achieving a PSA decline ≥ 50% in the absence of toxicity may continue to receive bicalutamide up to 72 weeks.
    Arm Title
    Arm B
    Arm Type
    Active Comparator
    Arm Description
    In weeks 1-12, patients receive oral enzastaurin hydrochloride twice daily. Patients with a PSA rise of > 50% above baseline or nadir, and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, may be started on bicalutamide before the end of week 12 at the discretion of the treating physician. In weeks 13-44, patients with a PSA rise of ≥ 50% above baseline or nadir, and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, are removed from study. Patients receive oral enzastaurin twice daily and oral bicalutamide once daily. Patients achieving a PSA decline ≥ 50% in the absence of toxicity may continue on this combination therapy up to 72 weeks.
    Intervention Type
    Drug
    Intervention Name(s)
    bicalutamide
    Intervention Description
    Given orally
    Intervention Type
    Drug
    Intervention Name(s)
    enzastaurin hydrochloride
    Intervention Description
    Given orally
    Primary Outcome Measure Information:
    Title
    Comparison of proportion of patients with undetectable prostate-specific antigen PSA level (< 0.2 ng/mL) at 44 weeks
    Secondary Outcome Measure Information:
    Title
    Comparison of proportion of patients achieving ≥ 85% PSA decline at 44 weeks
    Title
    PSA response
    Title
    Time to PSA progression
    Title
    Time to PSA nadir
    Title
    Duration of PSA response
    Title
    PSA slope at baseline, during, and after treatment
    Title
    Effect of Gleason score and prior hormonal therapy on PSA response to treatment

    10. Eligibility

    Sex
    Male
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    DISEASE CHARACTERISTICS: Histologically confirmed prostate cancer Hormone-sensitive disease, as evidenced by a serum total testosterone level > 150 ng/dL No evidence of metastatic disease on physical exam, CT abdomen/pelvis (or MRI), chest x-ray or CT scan and bone scan within 6 weeks prior to randomization Underwent prior definitive surgery or radiotherapy Must have evidence of biochemical failure after primary therapy and subsequent progression as determined by 1 of the following: Prostate-specific antigen (PSA) ≥ 0.4 ng/mL (in case of radical prostatectomy) PSA rise ≥ 2 ng/mL above the nadir PSA (in case of radiotherapy) Baseline PSA must be at least 2 ng/mL and no greater than 50 ng/mL PSA doubling time (PSADT) < 12 months PATIENT CHARACTERISTICS: ECOG performance status 0 - 1 Granulocytes ≥ 1,500/mm^3 Platelet count ≥ 75,000/mm^3 Serum creatinine normal or creatinine clearance ≥ 60 mL/min Serum total bilirubin ≤ 1.5 times upper limit of normal (ULN) Alkaline phosphatase ≤ 2.5 times ULN SGOT and SGPT < 2.5 times ULN PT/INR normal Fertile patients must use effective barrier contraception during and for at least 3 months after completion of study treatment No gastrointestinal (GI) tract disease resulting in: inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, or uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis) No history of allergic reactions attributed to compounds of similar chemical or biologic composition to enzastaurin hydrochloride or bicalutamide No uncontrolled intercurrent illness including, but not limited to, any of the following: Ongoing or active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situations that would limit compliance with study requirements A history of other malignancy is permitted if the patient is predicted to be disease-free for 2 years PRIOR CONCURRENT THERAPY: See Disease Characteristics More than 4 weeks since prior salvage therapy with intent to cure (i.e., surgery, radiotherapy, or other local ablative procedures) More than 4 weeks since prior prophylactic radiotherapy to prevent gynecomastia More than 1 year since prior therapy modulating testosterone levels (such as luteinizing-hormone releasing-hormone agonists/antagonists and antiandrogens) unless in the neoadjuvant or adjuvant setting No 5 alpha reductase inhibitors, ketoconazole, megestrol acetate, systemic steroids, or herbal supplements during PSA value collection At least 14 days since prior enzyme-inducing anti-epileptic drugs (EIAEDs) Patients who must begin EIAED therapy while on study are allowed to remain No concurrent combination antiretroviral therapy for HIV-positive patients No concurrent anticoagulant therapy Low dosage acetyl salicylic acid ≤ 325 mg/day allowed No other concurrent investigational agents or anticancer therapy (i.e., chemotherapy, immunotherapy, radiotherapy, surgery for cancer, or experimental medications) No history of allergic reactions attributed to compounds of similar chemical or biologic composition to enzastaurin or bicalutamide Prior neoadjuvant and/or adjuvant therapy ≤ 4 weeks prior to randomization (i.e., hormones, chemotherapy, vaccines, or experimental agents) allowed if PSA rise and PSADT were documented after testosterone level was > 150 ng/dL
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Anna C. Ferrari, MD
    Organizational Affiliation
    NYU Langone Health
    Official's Role
    Study Chair
    First Name & Middle Initial & Last Name & Degree
    Ronald Rodriguez, MD, PhD
    Organizational Affiliation
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    12. IPD Sharing Statement

    Learn more about this trial

    Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer

    We'll reach out to this number within 24 hrs